LAB vs LEN
Standard Biotools Inc (LAB) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
LEN (LEN) common stock.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
LEN does not have a complete income-statement cache yet.
LAB currently screens at market cap $317.1M. LEN currently screens at market cap $0.
Not investment advice. Open the LAB and LEN stock pages for the full models.
Not investment advice.